OBJECTIVE: Macrophage activation syndrome (MAS) in systemic onset juvenile idiopathic arthritis (SoJIA) is considered to be an acquired form of familial haemophagocytic lymphohistiocytosis (fHLH). FHLH is an autosomal recessive disorder, characterized by diminished NK cell function and caused by mutations in the perforin gene (PRF1) in 20-50% of patients. Interestingly, SoJIA patients display decreased levels of perforin in NK cells and diminished NK cell function as well. Here, we analysed PRF1 and its putative promoter in SoJIA patients with or without a history of MAS. METHODS: DNA of 56 SoJIA patients (41 Italian and 15 Dutch) was isolated. Of these, 15 (27%) had a confirmed history of MAS. We sequenced PRF1 and 1.5 kb of the 5'-upstream region. DNA sequence variations in the promoter region were functionally tested in transfection experiments using a human NK cell line. RESULTS: We detected a previously undescribed sequence variation (-499 C > T) in the promoter of PRF1 in 18% of the SoJIA patients. However, transfection experiments did not show functional implications of this variation. Secondly, we found that 11 of 56 (20%) SoJIA patients were heterozygous for missense mutations in PRF1. In particular, we found a high prevalence of the Ala91Val mutation, a variant known to result in defective function of perforin. Interestingly, the prevalence of Ala91Val in SoJIA patients with a history of MAS (20%) was increased compared with SoJIA patients without MAS (9.8%). One SoJIA patient, heterozygous for Ala91Val, showed profound decreased perforin levels at the time of MAS. CONCLUSIONS: These findings suggest that PRF1 mutations play a role in the development of MAS in SoJIA patients.
OBJECTIVE:Macrophage activation syndrome (MAS) in systemic onset juvenile idiopathic arthritis (SoJIA) is considered to be an acquired form of familial haemophagocytic lymphohistiocytosis (fHLH). FHLH is an autosomal recessive disorder, characterized by diminished NK cell function and caused by mutations in the perforin gene (PRF1) in 20-50% of patients. Interestingly, SoJIA patients display decreased levels of perforin in NK cells and diminished NK cell function as well. Here, we analysed PRF1 and its putative promoter in SoJIA patients with or without a history of MAS. METHODS: DNA of 56 SoJIA patients (41 Italian and 15 Dutch) was isolated. Of these, 15 (27%) had a confirmed history of MAS. We sequenced PRF1 and 1.5 kb of the 5'-upstream region. DNA sequence variations in the promoter region were functionally tested in transfection experiments using a human NK cell line. RESULTS: We detected a previously undescribed sequence variation (-499 C > T) in the promoter of PRF1 in 18% of the SoJIA patients. However, transfection experiments did not show functional implications of this variation. Secondly, we found that 11 of 56 (20%) SoJIA patients were heterozygous for missense mutations in PRF1. In particular, we found a high prevalence of the Ala91Val mutation, a variant known to result in defective function of perforin. Interestingly, the prevalence of Ala91Val in SoJIA patients with a history of MAS (20%) was increased compared with SoJIA patients without MAS (9.8%). One SoJIA patient, heterozygous for Ala91Val, showed profound decreased perforin levels at the time of MAS. CONCLUSIONS: These findings suggest that PRF1 mutations play a role in the development of MAS in SoJIA patients.
Authors: Claudia Macaubas; Khoa D Nguyen; Ariana Peck; Julia Buckingham; Chetan Deshpande; Elizabeth Wong; Heather C Alexander; Sheng-Yung Chang; Ann Begovich; Yue Sun; Jane L Park; Kuang-Hung Pan; Richard Lin; Chih-Jian Lih; Erin M Augustine; Carolyn Phillips; Andreas V Hadjinicolaou; Tzielan Lee; Elizabeth D Mellins Journal: Clin Immunol Date: 2011-12-28 Impact factor: 3.969
Authors: Kejian Zhang; Michael B Jordan; Rebecca A Marsh; Judith A Johnson; Diane Kissell; Jarek Meller; Joyce Villanueva; Kimberly A Risma; Qian Wei; Peter S Klein; Alexandra H Filipovich Journal: Blood Date: 2011-08-31 Impact factor: 22.113
Authors: Amy E Verrinder; Joanna L S Marsden; Mary A Slatter; Leigh McDonald; Chris M Bacon; Joaquim Majo; Andrew R Gennery Journal: Immunol Res Date: 2019-06 Impact factor: 2.829
Authors: Ilia Voskoboinik; Paul Lacaze; Helena Sung-In Jang; Thijs Flinsenberg; Suran L Fernando; Ian Kerridge; Moeen Riaz; Robert Sebra; Kevin Thia; Taherah Noori; Eric E Schadt; John J McNeil; Joseph A Trapani Journal: Blood Date: 2020-02-20 Impact factor: 22.113
Authors: Grant S Schulert; Mingce Zhang; Ndate Fall; Ammar Husami; Diane Kissell; Andrew Hanosh; Kejian Zhang; Kristina Davis; Jeffrey M Jentzen; Lena Napolitano; Javed Siddiqui; Lauren B Smith; Paul W Harms; Alexei A Grom; Randy Q Cron Journal: J Infect Dis Date: 2015-11-23 Impact factor: 5.226